智通财经网·2025-12-24 07:50Group 1 - Sanofi has agreed to acquire Denali Therapeutics for approximately $2.2 billion to expand its vaccine product line focused on influenza vaccines [1] - The acquisition will be at a cash price of $15.50 per share, representing a 39% premium over Denali's closing price on Tuesday [1] - This acquisition will provide Sanofi with an already marketed hepatitis B vaccine and an experimental shingles vaccine currently in early human trials, enhancing its presence in the adult vaccination market [1] Group 2 - Sanofi emphasized that the acquisition is not expected to impact its financial guidance for 2025 and is anticipated to be completed in the first quarter of 2026 [1] - Shortly before announcing the acquisition, Sanofi disclosed that its investigational multiple sclerosis drug tolebrutinib faced a rejection from the FDA [2] - The R&D head of Sanofi expressed disappointment regarding the FDA's decision, noting a significant and substantive shift in direction compared to previous feedback from the agency [3]